Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DNase Clear all
Completed Not applicable Interventional Results available

Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients

NCT00671723
View directory record Official record
Conditions
Atelectasis
Interventions
Normal saline:, Hypertonic Saline, Dornase alpha
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 90 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Management of Pleural Space Infections

NCT03873766
View directory record Official record
Conditions
Empyema, Pleural, Parapneumonic Effusion
Interventions
Intrapleural Medications, Surgery, Pleural Sampling, Pleural fluid drainage, Protocol Image #1, Surgical Consultation, Protocol Image #2: Chest X-ray PA/Lateral, Quality of Life
Drug · Procedure · Radiation + 2 more
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Sep 2, 2026, 6:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease

NCT02702518
View directory record Official record
Conditions
Ocular Graft vs Host Disease, Dry Eye
Interventions
rhDNase I, Vehicle
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Not applicable Interventional

Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients

NCT01095276
View directory record Official record
Conditions
Atelectasis, Ventilation, Mechanical
Interventions
Pulmozyme (nebulized dornase alpha), Saline
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2010 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

Treatment of Complicated Parapneumonic Effusion With Fibrinolytic Therapy Versus VATs Decortication

NCT03583931
View directory record Official record
Conditions
Parapneumonic Effusion, Empyema, Pleural, Coagulopathy
Interventions
VATS Decortication, Fibrinolytic Therapy
Procedure · Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Sep 2, 2026, 6:45 PM EDT
Withdrawn Phase 3 Interventional

Pulmozyme in Cystic Fibrosis With Sinusitis

NCT01155752
View directory record Official record
Conditions
Sinusitis, Cystic Fibrosis
Interventions
Pulmozyme single use ampule, placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing if Tartarase Can Remove Dental Tartar

NCT06139835
View directory record Official record
Conditions
Dental Calculus
Interventions
Tartarase
Biological
Lead sponsor
Pontis Biologics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Huntington, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis

NCT00416182
View directory record Official record
Conditions
Sinusitis, Cystic Fibrosis
Interventions
Pulmozyme (dornase alfa), Placebo
Drug
Lead sponsor
University of Vermont
Other
Eligibility
5 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers

NCT01516372
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GEn 1200mg, Gen 6000 mg, GEn Placebo, Moxifloxacin Placebo, Moxifloxacin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2021 · Synced Sep 2, 2026, 6:45 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

NCT04445285
View directory record Official record
Conditions
Covid19
Interventions
Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase), 0.9%sodium chloride
Drug
Lead sponsor
Jon Simmons
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Phase 2 Interventional

T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant

NCT00089180
View directory record Official record
Conditions
Actinic Keratosis, Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Interventions
liposomal T4N5 lotion, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 2, 2026, 6:45 PM EDT
Not listed Phase 1 Interventional

Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions

NCT02135588
View directory record Official record
Conditions
Loculated or Non-draining Malignant Pleural Effusions
Interventions
Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)
Drug
Lead sponsor
Eastern Regional Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 2, 2026, 6:45 PM EDT
Enrolling by invitation Not applicable Interventional

I-TRUST: Implementation of Teleophthalmology in Rural Health Systems Study

NCT05254535
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
I-SITE
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 2, 2026, 6:45 PM EDT
Withdrawn Phase 4 Interventional

Early Intrapleural TPA Instillation Versus Late

NCT03167281
View directory record Official record
Conditions
Tissue Plasminogen Activator
Interventions
early tPA and DNase
Combination Product
Lead sponsor
Prisma Health-Midlands
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 2, 2026, 6:45 PM EDT
Not listed Phase 3 Interventional

T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum

NCT00002811
View directory record Official record
Conditions
Precancerous Condition
Interventions
liposomal T4N5 lotion
Drug
Lead sponsor
Applied Genetics
Industry
Eligibility
2 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
7
States / cities
Miami Beach, Florida • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 2, 2026, 6:45 PM EDT
Withdrawn Phase 3 Interventional

Empyema Treated With tPA & DNAse

NCT01862458
View directory record Official record
Conditions
Empyema
Interventions
tPA alone, tPA plus dornase
Biological
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

NCT06350474
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase)
Other
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 2, 2026, 6:45 PM EDT
Recruiting Phase 4 Interventional

Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema

NCT07095361
View directory record Official record
Conditions
Pleural Infection Bacterial, Pleural Infections, Pleural Infections and Inflammations, Empyema, Pleural, Empyema, Complicated Pleural Effusion/ Empyema, Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion
Interventions
Fibrinolytic once daily, Fibrinolytic twice daily, DNA degradation once daily, DNA degradation twice daily
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
New Haven, Connecticut • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Phase 1 Interventional

Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94

NCT00617032
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tgAAC94 gene therapy vector, tgAAC94 placebo
Genetic
Lead sponsor
Targeted Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Los Angeles, California • Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2008 · Synced Sep 2, 2026, 6:45 PM EDT
Recruiting Not applicable Interventional

Chest Drain Regular Flushing in Complicated Parapneumonic Effusions and Empyemas

NCT06427538
View directory record Official record
Conditions
Empyema, Pleural, Pleural Infection
Interventions
Saline Flush
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Sterling Heights, Michigan • Omaha, Nebraska • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT00454818
View directory record Official record
Conditions
Heart Failure, Congestive, Dilated Cardiomyopathy
Interventions
MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study), Placebo Infusion, MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
Genetic · Procedure
Lead sponsor
Celladon Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
22
States / cities
San Diego, California • Gainesville, Florida • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 2, 2026, 6:45 PM EDT
Not yet recruiting Phase 4 Interventional

Flush, Lyse, Operate

NCT07592520
View directory record Official record
Conditions
Complicated Parapneumonic Effusion, Empyema, Pleural
Interventions
Intrapleural Saline with possible escalation to intraplerual alteplase and dornase.
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Hanover, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 2, 2026, 6:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

DNase Treatment for Dry Eyes

NCT02193490
View directory record Official record
Conditions
Dry Eye
Interventions
DNase, Vehicle
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 2, 2026, 6:45 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

NCT00179998
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Recombinant Human DNase (Pulmozyme), Placebos
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 30 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 2, 2026, 6:45 PM EDT